StocksMedium•29 October 2026•
1 min read
Propanc Biopharma Receives Nasdaq Delisting Notice Over Minimum Bid Price
Key Facts
1Propanc Biopharma received a notice from Nasdaq stating its stock failed to meet the minimum bid price requirement.
2Nasdaq indicated the company is ineligible for a standard compliance period due to a recent reverse stock split.
Propanc Biopharma received a notice from Nasdaq stating its common stock failed to meet the minimum bid price requirement for continued listing. Benzinga reported that Nasdaq deemed the company ineligible for a standard compliance period to regain requirements due to a recent reverse stock split.
PPCB closed at $2.11 on October 28, 2026, with the stock trading between a day low of $2.09 and a high of $2.5 during that session. The delisting notice follows the company's inability to maintain the necessary price levels required by the exchange's regulatory framework.